Beiträge AKTUELLES Mo, 07.04.2025 MAESTRIA-AFNET 10 – Collection of blood samples Collection and procedure of blood samples within MAESTRIA-AFNET 10 Collection:A total of 26 tubes will be collected for one patient: Please find a detailed procedure for the collection of blood samples in the study protocol (see Appendix 7, page 47+48). Labelling:The samples collected will … Read more
Beiträge AKTUELLES Mo, 07.04.2025 MAESTRIA-AFNET 10 – 3rd Investigator Meeting Prof. Goette emphasized that it is very important not only to recruit further permanent AF patients, but also to keep the patients in the study until 1-year follow up. This final data is essential to correlate it with the data from Baseline visit. All collected … Read more
Prof. Dr. med. Götz Thomalla (UKE) and Dr. med. Märit Jensen (UKE) have recorded a video on the new EAST-STROKE trial in layman’s terms.
The EAST-STROKE (‘Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE’) trial is led by scientist from the University Medical Centre Hamburg-Eppendorf (UKE) and investigates whether early rhythm-control treatment can effectively and safely prevent strokes. The project is funded by the EU as part of ‘Horizon Europe’. AFNET is partner for dissemination and exploitation.
AFNET associated events:
30th of August 2024, 10:27 am (CEST/German time) / 9:27 am (BST/British time): “Prague”, Adjunct pharmacology in PCI: beyond antiplatelet therapy, the next chapter – discussion (Renate Schnabel)
More Information
A subgroup analysis of the NOAH – AFNET 6 trial revealed: In patients with device-detected atrial fibrillation and a prior stroke, oral anticoagulation increases bleeding without a clear reduction in stroke. This finding was presented by Prof. Paulus Kirchhof, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, in a late-breaking clinical trials session at the annual congress of the American Heart Rhythm Society (HRS) in Boston, USA, on 19.05.2024 (1).
Device-detected atrial fibrillation (DDAF) are short and typically rare episodes of atrial fibrillation (AF) detected by pacemakers, defibrillators, and implanted loop recorders capable of continuous rhythm monitoring. Device-detected atrial fibrillation is found in every fifth patient with a cardiac implanted electronic device (2). Device-detected atrial fibrillation can lead to stroke, but the stroke risk in patients with device-detected atrial fibrillation appears lower than the stroke risk in patients with ECG-documented atrial fibrillation (1%/year).
Anticoagulation effectively prevents stroke in patients with ECG-documented AF. It is particularly effective in patients with AF and a prior stroke or transient ischemic attack (TIA) who are at high risk of recurrent stroke. In patients with a prior stroke without ECG-documented AF, oral anticoagulants mainly increase bleeding with only a weak effect on ischemic stroke.
Prof Breithardt was honoured with the AFNET Lecture Award at the AFNET general meeting during the DGK 2024 annual conference in Mannheim. In this video you can see his lecture at the award ceremony.
16th of May 2024, 7:00 pm (CEST/German time) / 1:00 pm (EASTERN/Boston time): “160 – BCEC “, Cost Benefit Analysis: Where Does Remote Monitoring Land? (Thorsten Lewalter)
More information
17th of May 2024, 10:30 am (CEST/German time) / 4:30 pm (EASTERN/Boston time): “PO-01-190”, The Role Meta-analysis of RNAseq Data from Two Large Atrial Tissue Banks Identifies More than 8000 Transcripts Associated with AF and Suggests a Prominent Role for Mitochondrial Processes and Energy Metabolism: the CATCH ME and RACE V Consortia (various speakers)
More information
An analysis of the biomolecule substudy of the EAST – AFNET 4 trial revealed: biomolecule concentrations in the blood of patients with atrial fibrillation can be used to identify patients at high and low cardiovascular risk. Today the findings were presented by Prof. Larissa Fabritz, University Medical Center Hamburg Eppendorf, Hamburg, Germany, at the Frontiers in CardioVascular Biomedicine Congress in Amsterdam and published in Cardiovascular Research (1).
Atrial Fibrillation (AF) is the most common arrhythmia in elderly people. AF often occurs in patients with cardiovascular comorbidities with shared disease mechanisms. Little is known about the disease processes leading to AF-related complications and their interactions in patients with AF.
In patients with device-detected atrial fibrillation and a high comorbidity burden, oral anticoagulation increases bleeding without a clear reduction in stroke. This is the main finding of a sub-analysis of the NOAH – AFNET 6 trial presented by Dr Julius Nikorowitsch, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, in a late-breaking science session at the annual congress of the European Heart Rhythm Association (EHRA) in Berlin, Germany, today and simultaneously published in the European Heart Journal (1).
Device-detected atrial fibrillation (DDAF) are short and typically rare episodes of atrial fibrillation (AF) detected by pacemakers, defibrillators, and implanted loop recorders capable of continuous rhythm monitoring. Device-detected atrial fibrillation is found in every fifth patient with a cardiac implanted electronic device (2). Device-detected atrial fibrillation can lead to stroke, but the stroke risk in patients with device-detected atrial fibrillation appears lower than the stroke risk in patients with ECG-documented atrial fibrillation.
